Hervana Bio

Company Overview

Snapshot

Founded in June 2008 by Rachel Teitelbaum, PhD, Hervana Bio operates with 1–10 employees. The company has raised $1.1 million across two funding rounds. In April 2024, Hervana Bio was highlighted for developing the first new, non-hormonal contraceptive in 60 years.

Business overview

Hervana Bio is a biopharmaceutical company focused on developing women's health products. The company's core technology is a non-hormonal female contraceptive platform, LJ-102, designed to offer protection against sexually transmitted infections. This technology aims to provide a highly effective, long-lasting contraceptive solution without the drawbacks of current hormone-based methods, targeting markets where existing contraception options may be contraindicated, undesirable, or socially unacceptable. Hervana Bio operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In April 2024, Hervana Bio was featured for its pioneering work in developing a new non-hormonal contraceptive, marking a significant advancement in women's health. This signals a potential breakthrough in reproductive medicine, addressing a long-standing need for alternative contraceptive methods and positioning Hervana Bio as an innovator in the pharmaceutical landscape.

Company Intelligence Q&A

What is Hervana Bio's primary product?

Hervana Bio's primary product is LJ-102, a non-hormonal female contraceptive technology that also offers protection against sexually transmitted infections.

When was Hervana Bio founded and by whom?

Hervana Bio was founded in June 2008 by Rachel Teitelbaum, PhD.

What was a significant grant received by Hervana Bio?

In December 2012, Hervana Bio received a grant from the Bill & Melinda Gates Foundation for its contraceptive development.

What is the total capital raised by Hervana Bio?

Hervana Bio has raised $1.1 million across two funding rounds.

What was a key development highlighted in April 2024?

In April 2024, Hervana Bio was noted for developing the first new, non-hormonal contraceptive in 60 years.